Prostate, Phase I-II

Phase 1/2 Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Volunteers
Health Professionals

What is the purpose of this trial?

Assessment of the safety and efficacy of HLD-0915 as monotherapy in patients with metastatic castration resistant prostate cancer (mCRPC) that have progressed on prior systemic therapies, once a recommended dose for expansion (RDE) has been determined in Phase 1 of the trial.

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Amanda Davis

amanda.davis@yale.edu

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Joseph Kim, MD
Associate Professor of Internal Medicine (Medical Oncology); Director, Prostate Cancer Research; Lecture Coordinator in Hematology/Oncology, Yale Affiliated Hospital Program

Sub-Investigators

Last Updated
06/07/2026
Study IRB
#2000040328